Langerhans cell histiocytosis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Langerhans cell histiocytosis}} | {{Langerhans cell histiocytosis}} | ||
{{CMG}} | {{CMG}} | ||
Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | |||
==Overview== | ==Overview== |
Revision as of 19:52, 13 September 2012
Langerhans cell histiocytosis Microchapters |
Differentiating Langerhans cell histiocytosis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Langerhans cell histiocytosis secondary prevention On the Web |
American Roentgen Ray Society Images of Langerhans cell histiocytosis secondary prevention |
Langerhans cell histiocytosis secondary prevention in the news |
Directions to Hospitals Treating Langerhans cell histiocytosis |
Risk calculators and risk factors for Langerhans cell histiocytosis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
- Complications may include:
- Diffuse interstitial pulmonary fibrosis
- Spontaneous pneumothorax
- Children may also develop:
- Anemia caused by spreading of the tumors to the bone marrow
- Diabetes insipidus
- Lung problems that lead to lung failure
- Problems with the pituitary gland that lead to growth failure